Therefore, in this study, we attempted to convert the negative CTLA4-CD86/CD86 signal by generating a novel CTLA4 signaling pathway in T cells to disrupt the interaction of immune checkpoint inhibitors CTLA4 and CD80/CD86 to effectively treat CD80/CD86-expressing cancer. This evidence concerns the gene CD86 and cancer.